meu10 Antibody

What is Meu10 and how was it originally identified in research settings?

Meu10 is a glycosylphosphatidylinositol (GPI)-anchored protein discovered through a novel surface protein-labeling protocol using Pneumocystis murina. The identification process involved biotin labeling of purified P. murina surface proteins followed by LC-MS analysis to determine peptide sequences. The tandem mass spectral data was then used to query the NCBI RefSeq protein sequence database for fungi (Taxonomy ID 4751) and the P. murina draft genome database to identify the peptides . This technique facilitated the discovery of Meu10 alongside other surface proteins, differentiating it from previously known major surface glycoproteins (MSGs) of Pneumocystis.

How is Meu10 structurally characterized and what is its distribution across different Pneumocystis species?

Meu10 is characterized as a type I transmembrane protein with a GPI anchor based on TMHMM analysis . The protein contains a large ectodomain that makes it potentially accessible to antibodies and immune recognition. Importantly, Meu10 has been found to be conserved across different Pneumocystis species, specifically in both P. murina (mouse pathogen) and P. jirovecii (human pathogen) . This conservation suggests evolutionary importance and makes it a promising target for cross-species research and potential therapeutic development.

What is the cellular localization pattern of Meu10 on Pneumocystis organisms?

Immunofluorescence studies have demonstrated that Meu10 is expressed on the extracellular surface of both major morphological forms of Pneumocystis: the cyst and the trophic forms (trophs) . This dual localization is significant because it means antibodies targeting Meu10 could potentially recognize the pathogen throughout its life cycle. Visualization using anti-Meu10 serum (generated from mice immunized with Meu10 peptide pools) conjugated with DyLight 488 and counterstained with DAPI has confirmed this surface expression pattern, while control studies with naive serum showed minimal non-specific staining .

What are the established protocols for recombinant expression of Meu10 for antibody generation and characterization?

Recombinant Meu10 expression has been successfully achieved through the following methodological approach:

• The P. murina Meu10 sequence is synthesized and cloned into an expression vector (e.g., pBudCE4.1) under a strong promoter (CMV promoter)

• A C-terminal tag (such as myc) is included for detection purposes

• 293 cells are transfected using specific parameters (1,500 V, 30 ms, 1 pulse with neon transfection system)

• Cells are lysed using appropriate buffer with protease inhibitors

• Lysate is sonicated and harvested for subsequent applications

This expression system produces detectable Meu10 protein that can be used for antibody generation and characterization experiments.

What immunological detection methods are most effective for Meu10 antibody validation?

Several complementary detection methods have proven effective for Meu10 antibody validation:

Western Blotting Protocol:

• Cell lysates containing recombinant Meu10 are boiled at 95°C in 1× LDS buffer

• Samples are loaded onto 4-20% Bis-Tris gels and transferred to membranes

• Membranes are blocked with TBST plus 5% dry milk

• Primary antibody (anti-myc or anti-Meu10) is applied overnight at 4°C

• After washing, secondary antibody conjugated to HRP is applied

• Visualization is performed using chemiluminescent substrate

ELISA Protocol:

• Cell lysates (150 ng/well) in coating buffer are added to 96-well plates

• Plates are incubated overnight, washed, and blocked

• P. murina convalescent-phase serum or naive serum is added

• After washing, secondary antibody (goat anti-mouse IgG) is applied

• TMB substrate is used for development and absorbance measured at 450 nm

These methodologies provide complementary validation approaches to confirm Meu10 antibody specificity and binding characteristics.

How can researchers effectively visualize Meu10 localization on Pneumocystis organisms?

Immunofluorescence microscopy has been validated as an effective visualization technique for Meu10 localization:

• P. murina samples are fixed onto glass slides using heat fixation followed by ice-cold methanol

• Slides are washed with PBS and blocked with PBS-5% dry milk for 15 minutes

• Anti-Meu10 serum (diluted 1:1,000 in PBS) is applied for 15 minutes

• After washing, secondary antibody (goat anti-mouse IgG conjugated to DyLight 488) is applied

• Counterstaining with DAPI (1:2,000 for 15 minutes) allows visualization of nuclei

• Slides are mounted with appropriate media and visualized at high magnification (×63)

This method has demonstrated specific staining of both cyst and trophic forms, confirming the surface localization of Meu10 across different developmental stages of the organism.

What evidence supports the potential of Meu10 as a target for vaccine or therapeutic monoclonal antibody development?

Several experimental findings support Meu10's potential as a vaccine or therapeutic target:

• Natural immunogenicity: Studies have demonstrated that Meu10 antibodies are naturally generated during P. murina infection, indicating that the protein is recognized by the host immune system under physiological conditions

• Surface accessibility: Immunofluorescence studies confirm that Meu10 is accessible on the pathogen surface, making it a viable target for antibody binding in vivo

• Conservation across species: Meu10 is conserved between P. murina and the human pathogen P. jirovecii, suggesting potential cross-reactivity of therapeutic antibodies

• Large ectodomain: The protein's structure features a substantial extracellular domain that provides ample epitopes for antibody recognition

These characteristics parallel those of successful antibody targets in other pathogens, such as the hMPV-F protein targeted by M8C10 antibody, which has demonstrated significant neutralization capacity and in vivo protection .

How can T-cell and B-cell epitope mapping of Meu10 inform improved antibody development?

Epitope mapping of Meu10 can strategically enhance antibody development through:

T-cell Epitope Identification Process:

• Protein sequences are analyzed for putative MHCII binding regions

• Peptides from these regions are synthesized for experimental validation

• T-cell ELISpot studies measure stimulation responses to identify immunogenic epitopes

B-cell Epitope Characterization:

• Recombinant Meu10 protein is expressed with detection tags

• ELISA assays using convalescent sera identify regions recognized during natural infection

• Competitive binding assays can determine distinct epitope groups

Research has confirmed that Meu10 contains both T-cell and B-cell epitopes, which are part of the natural host response to P. murina infection . Understanding these epitope patterns can inform the design of antibodies that target the most immunogenic and functionally relevant regions of the protein, potentially enhancing therapeutic efficacy.

What experimental approaches can assess the neutralizing capacity of anti-Meu10 antibodies?

Drawing from methodologies used for other pathogen-neutralizing antibodies, researchers can adapt several approaches to evaluate anti-Meu10 antibody efficacy:

In Vitro Neutralization Assays:

• Plaque reduction neutralization tests similar to those used for hMPV neutralizing antibodies

• Serial dilutions of anti-Meu10 antibodies mixed with Pneumocystis organisms

• Susceptible cell lines exposed to antibody/organism mixtures

• Organism growth quantified after appropriate incubation period

• IC50 values calculated to determine neutralization potency

In Vivo Protection Models:

• Animal models (e.g., immunocompromised mice) receive prophylactic anti-Meu10 antibodies

• Control groups receive non-specific antibodies

• Animals are challenged with Pneumocystis infection

• Lung fungal burden is measured to assess protection

• Dose-response relationships established to determine effective concentrations

While these specific assays have not yet been reported for Meu10, they represent logical adaptations of methods that have successfully demonstrated protection for other microbial targets, such as the hMPV challenge studies with the M8C10 antibody .

How can researchers address potential antibody escape mutations in Meu10?

Addressing antibody escape presents several methodological challenges. Researchers studying other pathogen antibodies have employed monoclonal antibody-resistant mutant (MARM) generation approaches, which could be adapted for Meu10:

• Culture Pneumocystis organisms under increasing concentrations of anti-Meu10 antibodies

• Isolate organisms that grow under selection pressure

• Sequence the Meu10 gene to identify potential resistance mutations

• Map mutations to the protein structure to understand escape mechanisms

• Design antibody cocktails targeting multiple epitopes to prevent escape

For example, in hMPV studies, researchers identified MARMs under antibody selective pressure that revealed mutations mapping to the trimeric surface, protease cleavage site, and C-terminus regions of the target protein . Similar approaches could identify potential resistance mechanisms for Meu10-targeting antibodies.

What machine learning approaches might enhance Meu10 antibody development and optimization?

Advanced computational methods could significantly accelerate Meu10 antibody research:

Active Learning for Antibody-Antigen Binding Prediction:
Recent advances in library-on-library approaches combined with machine learning can predict antibody-antigen interactions. Studies have shown that certain active learning algorithms can significantly outperform random data selection, reducing the number of required antigen mutant variants by up to 35% and accelerating the learning process .

For Meu10 specifically, researchers could:

• Generate antibody and Meu10 antigen variant libraries

• Implement active learning strategies to selectively test the most informative pairs

• Train machine learning models to predict binding interactions

• Iteratively improve predictions through targeted experimental validation

• Identify optimal antibody candidates with desired binding properties

This approach would be particularly valuable for addressing out-of-distribution prediction challenges that occur when test antibodies and antigens differ from training data .

What interdisciplinary approaches might advance therapeutic Meu10 antibody development?

Advancing Meu10 antibody development will likely require integration of multiple disciplines:

Structural Biology Integration:

• Determine the crystal structure of Meu10 alone and in complex with neutralizing antibodies

• Map epitopes with atomic-level precision to identify key binding determinants

• Use structure-guided design to enhance antibody affinity and specificity

Systems Immunology Approaches:

• Profile the natural antibody response to Meu10 during Pneumocystis infection

• Identify correlates of protection in naturally resistant hosts

• Characterize antibody Fc effector functions that contribute to protection

Translational Research Pathways:

• Develop humanized animal models for testing anti-Meu10 antibodies

• Establish physiologically relevant in vitro systems for screening

• Design antibody formulations suitable for respiratory delivery

By integrating these interdisciplinary approaches, researchers can address both fundamental questions about Meu10 immunity and practical challenges in therapeutic development, potentially creating effective antibody-based interventions for Pneumocystis infections.

What optimization strategies can improve recombinant Meu10 expression yields for antibody generation?

Optimizing recombinant Meu10 expression requires systematic evaluation of expression parameters:

Expression System Selection:

Codon Optimization Factors:

• Analyze the Meu10 sequence for rare codons that might limit expression

• Modify the coding sequence while maintaining the amino acid sequence

• Remove potential cryptic splice sites or regulatory elements

• Optimize GC content for expression host

Purification Tag Considerations:
Selecting appropriate tags and purification methods based on the research goals is critical. For Meu10, researchers have successfully used C-terminal myc tags for detection , but alternative approaches could include:

• His-tags for nickel affinity purification

• Fc-fusion for protein A/G purification

• Split inteins for tag-free purification